Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
about
Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myelomaAnalysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Multiple myeloma in the marrow: pathogenesis and treatments.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.Plasma cells as an innovative target in autoimmune disease with renal manifestations.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationDaratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaRe-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.The effect of novel therapies in high-molecular-risk multiple myeloma.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
P2860
Q28731827-CFBA4B5C-39FA-46A2-A88F-FFB1B9730732Q31119290-D72B790C-5CCA-41FD-A152-8D994114372DQ33434683-4EDE7EFC-B42B-460C-9302-7C4E4819EF5EQ34020937-AC666F40-737C-43C9-90F2-2C89A5725574Q35514038-D532A10A-4ED3-441C-91EB-585CFA791B6FQ36127898-165C281D-FEFC-4251-ACAF-A6E8D8892476Q36363958-D1AD307B-1426-4A63-943E-C9C7498D7032Q36725401-55F79500-4DA5-4F83-9E12-2C24E5A33E4BQ37076421-D948190F-A426-4496-AA91-E8A79C6E12D6Q38090691-A40F0BF2-62F7-4DDF-86C1-7EB00441E9B8Q38139998-54B6CB0B-08A1-4270-8F67-1B8AC0DC8ADFQ38753491-10DA6E88-1FEA-4A63-B2D5-6EBFDECC9BDCQ38817467-C5757DB6-37FF-4AED-9FC0-F5C8BD208D02Q38921332-7FB67716-A536-4986-B34B-B5B8EF87D1CBQ39146499-463EC90B-A332-4775-B571-FD05A51FE1FFQ41345636-0550B8C6-3A62-4937-BFC6-22CB127E6845Q42046550-56AA4F2B-C971-4C11-ACA5-AA613E8527C0Q45879904-5BFC9DAE-E3DE-4AFE-B3D3-EA9FEC2EE357Q47344786-06D71CEB-7632-4617-A710-D7FE1FA9A6DEQ47375990-4B5FEDE6-24CB-45C2-AE78-0EF7F9050393Q47688664-AA6BBF92-7C3B-407E-8AC8-0AFE27217CD2Q50026815-1833F156-4F5F-43C7-88C3-9CD2A6360953Q55021985-58787199-EA67-4889-970E-714943366221
P2860
Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Flow cytometric detection of a ...... in multiple myeloma patients.
@en
Flow cytometric detection of a ...... in multiple myeloma patients.
@nl
type
label
Flow cytometric detection of a ...... in multiple myeloma patients.
@en
Flow cytometric detection of a ...... in multiple myeloma patients.
@nl
prefLabel
Flow cytometric detection of a ...... in multiple myeloma patients.
@en
Flow cytometric detection of a ...... in multiple myeloma patients.
@nl
P2093
P50
P1433
P1476
Flow cytometric detection of a ...... t in multiple myeloma patients
@en
P2093
Anna Maria Santonocito
Patrizia Guglielmo
Rosario Giustolisi
Sabrina Bagnato
Ugo Consoli
P304
P356
10.1016/J.LEUKRES.2003.09.015
P577
2004-05-01T00:00:00Z